Corcept Therapeutics Incorporated (NASDAQ:CORT) Director Sells $149,776.00 in Stock

Corcept Therapeutics Incorporated (NASDAQ:CORT) Director Daniel N. Swisher, Jr. sold 2,200 shares of the company’s stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $68.08, for a total transaction of $149,776.00. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Daniel N. Swisher, Jr. also recently made the following trade(s):

• On Friday, January 10th, Daniel N. Swisher, Jr. sold 2,200 shares of Corcept Therapeutics stock. The shares were sold at an average price of $50.54, for a total transaction of $111,188.00.
• On Tuesday, December 10th, Daniel N. Swisher, Jr. sold 2,200 shares of Corcept Therapeutics stock. The stock was sold at an average price of $59.46, for a total transaction of $130,812.00.

Corcept Therapeutics Trading Up 3.0 %

NASDAQ:CORT traded up $2.04 on Wednesday, reaching $70.15. The stock had a trading volume of 641,148 shares, compared to its average volume of 852,447. The company has a market cap of $7.35 billion, a price-to-earnings ratio of 55.68 and a beta of 0.58. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.70 and a quick ratio of 3.64. Corcept Therapeutics Incorporated has a 12-month low of $20.84 and a 12-month high of $71.29. The firm’s fifty day moving average is $57.45 and its two-hundred day moving average is $48.88.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of CORT. M&G PLC acquired a new stake in shares of Corcept Therapeutics during the third quarter worth approximately $11,173,000. Synergy Asset Management LLC raised its holdings in shares of Corcept Therapeutics by 131.3% during the fourth quarter. Synergy Asset Management LLC now owns 462,411 shares of the biotechnology company’s stock valued at $22,369,000 after buying an additional 262,503 shares during the last quarter. Empowered Funds LLC acquired a new position in shares of Corcept Therapeutics during the third quarter valued at $1,784,000. Victory Capital Management Inc. raised its position in shares of Corcept Therapeutics by 49.2% during the 3rd quarter. Victory Capital Management Inc. now owns 41,823 shares of the biotechnology company’s stock worth $1,936,000 after buying an additional 13,787 shares in the last quarter. Finally, State Street Corp boosted its stake in Corcept Therapeutics by 0.6% during the 3rd quarter. State Street Corp now owns 3,519,263 shares of the biotechnology company’s stock valued at $162,871,000 after purchasing an additional 19,893 shares in the last quarter. 93.61% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on CORT shares. HC Wainwright reissued a “buy” rating and set a $80.00 price objective on shares of Corcept Therapeutics in a research note on Friday, February 7th. Canaccord Genuity Group raised their price target on shares of Corcept Therapeutics from $78.00 to $130.00 and gave the company a “buy” rating in a research report on Thursday, January 30th. Sandler O’Neill restated a “buy” rating on shares of Corcept Therapeutics in a research note on Friday, October 18th. Finally, StockNews.com cut Corcept Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 25th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $88.25.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.